NCT01971554View on ClinicalTrials.gov

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

October 14, 2013

Primary Completion Date

April 26, 2014

Study Completion Date

April 26, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MK-8666

MK-8666, capsules, oral, QD, Days 1 to 14

DRUG

Placebo

Placebo, capsules, oral, QD, Days 1 to 14

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01971554 - Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003) | Biotech Hunter | Biotech Hunter